Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by broxburnboyon Feb 23, 2012 2:57pm

358 Views

Post# 19575229

Extended test permission

I would expect that the positive next news item should be the renewal of production and a stated flow rate from the llanos well. Anyone heard?

From previous news item Jan 15:

The well was shut-in on Saturday, January 14 due to storage capacity and will remain suspended while the application is made to the Ministry of Mines in Colombia to put the well on an extended test. This application approval is expected to take up to four weeks, at which time the well can be put back on production and oil from the extended test sold to market.

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX